Complex Regional Pain Syndromes
Conditions characterized by pain involving an extremity or other body region, HYPERESTHESIA, and localized autonomic dysfunction following injury to soft tissue or nerve. The pain is usually associated with ERYTHEMA; SKIN TEMPERATURE changes, abnormal sudomotor activity (i.e., changes in sweating due to altered sympathetic innervation) or edema. The degree of pain and other manifestations is out of proportion to that expected from the inciting event. Two subtypes of this condition have been described: type I; (REFLEX SYMPATHETIC DYSTROPHY) and type II; (CAUSALGIA). (From Pain 1995 Oct;63(1):127-33)
Subtype terms (2)
More specific conditions that are subtypes of Complex Regional Pain Syndromes in the MeSH hierarchy.
- Causalgia
4 drugs (1 approved, 3 experimental)
- Reflex Sympathetic Dystrophy
9 drugs (5 approved, 4 experimental)
Drugs by status
Phase 4 trials (7)
Phase 3 trials (3)
Phase 1 trials (3)
Organizations
Organization Involved with Phase 4 Indications (3)
Organization Involved with Phase 3 Indications (8)
Organization Involved with Phase 2 Indications (20)
- Takeda
- Celgene
- Millennium Pharmaceuticals
- Merck KGaA
- Novartis
- National Institutes of Health (NIH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute of Nursing Research (NINR)
- Rockefeller University
- Drexel University
- McGill University
- Sorlandet Hospital HF
- University of California, Davis
- University of California, San Diego
- University of Sao Paulo
- Ludwig Maximilians University
- Department of Veteran Affairs
- German Federal Ministry of Education and Research
- Frontier Science & Technology Research Foundation, Inc.
- German Research Network on Neuropathic Pain
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (13)